ORGANIZATION
JGA Chief Wary of “Full” Off-Year Revision in 2025, Urges Broader Exemptions If Plan Goes Forward
The Japan Generic Medicines Association (JGA) certainly opposes the “full implementation” of the next “off-year” drug price revision in FY2025, but it is also preparing proposals that would be more palatable to financial authorities in case such discussions go forward.…
To read the full story
Related Article
ORGANIZATION
- EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
- Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
February 24, 2026
- JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
February 20, 2026
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





